Table 9.

Longitudinal studies on serum CA125 levels and survival in ovarian cancer

First Author, Year, Study Place	Data Collection	Study Design	Sample Size	Groups being Compared	RR/HR, (95% CI), P-Value	Conclusion	Variables Adjusted for
Riedinger JM, 2007, France [47]	1988 to 1996	Multicentric study	494	≥ 75% decrease, < 75% decrease or increase	Univariate- 1.92 (1.34--2.74), < 0.0001 3.08 (2.10--4.50), < 0.0001 Multivariate-0.90 (0.59--1.39), NS 0.97 (0.59--1.59), NS	The CA125 change after first course of CT was independent prognostic factors for both achievement of pathological complete response and overall survival.	Age, Histology FIGO stage, Residual tumor
Markman M, 2006, USA [37]	NA	Longitudinal study	291	I > 100, ≤ 35 u/ml II 36--99, ≤ 35 u/ml III > 100, 36--99 u/ml	I - 3.0 (1.7--8.6), 0.0001 II - 1.6 (0.9--2.8), 0.09 III-1.8 (1.0--3.5), 0.07	While pretreatment CA125 values did not correlate with survival, the concentration of CA125 8 weeks after initiation of therapy was a powerful independent prognostic factor.	Age, performance status, disease stage, measurable disease, treatment, tumor necrosis, stromal sclerosis